00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
20:04 , Apr 20, 2018 |  BC Week In Review  |  Company News

ApolloBio licenses Tocagen's immunotherapy

Tocagen Inc. (NASDAQ:TOCA) granted ApolloBio Corp. (NEEQ:430187) exclusive rights to develop and commercialize vocimagene amiretrorepvec/extended release flucytosine (Toca 511/Toca FC) in Taiwan and China, including Hong Kong and Macau, to treat high grade glioma (HGG)....
22:53 , Jan 5, 2018 |  BC Week In Review  |  Company News

Inovio, ApolloBio amend VGX-3100 deal

Inovio Pharmaceuticals Inc. (NASDAQ:INO) and ApolloBio Corp. (NEEQ:430187) amended a deal granting ApolloBio exclusive rights to develop and commercialize VGX-3100 in Taiwan and China, including Hong Kong and Macau, to treat or prevent pre-cancerous infections...
20:19 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Inovio resumes VGX-3100 HPV cancer program

Inovio Pharmaceuticals Inc. (NASDAQ:INO) said FDA lifted a clinical hold on its Phase III program of VGX-3100 to treat cervical dysplasia caused by HPV. The company plans to immediately begin a pair of Phase III...
22:46 , Jun 8, 2017 |  BC Extra  |  Clinical News

Inovio resumes VGX-3100 HPV cancer program

Inovio Pharmaceuticals Inc. (NASDAQ:INO) gained $0.80 (11%) to $8.19 on Thursday after the company said FDA lifted a clinical hold on its Phase III program of VGX-3100 to treat cervical dysplasia caused by HPV. The...
00:28 , May 2, 2017 |  BC Week In Review  |  Clinical News

Inovio starts Ph II of HPV vaccine VGX-3100

Inovio Pharmaceuticals Inc. (NASDAQ:INO) began a Phase II trial to evaluate intramuscular VGX-3100 in 36 patients with vulvar intraepithelial neoplasia (VIN). The open-label trial is evaluating the primary endpoint of clearance of high-grade lesions and...
20:28 , Feb 16, 2017 |  BC Week In Review  |  Company News

Inovio, ApolloBio deal

Inovio granted ApolloBio exclusive rights to develop and commercialize VGX-3100 in Taiwan and China, including Hong Kong and Macau, to treat or prevent pre-cancerous infections and dysplasias tied to HPV. Inovio will receive $3 million...
22:25 , Feb 13, 2017 |  BC Extra  |  Company News

Inovio grants ApolloBio China rights to HPV candidate

Inovio Pharmaceuticals Inc. (NASDAQ:INO) granted ApolloBio Corp. (NEEQ:430187) rights in Greater China to vaccine VGX-3100 to treat or prevent pre-cancerous infections and dysplasias tied to HPV. Inovio spokesperson Jeff Richardson told BioCentury the company expects...